Syros to Present on SY-1425 in Combination with Standard-of-Care and Targeted Therapies in Genomically Defined Subsets of AML and MDS Patients
Stock Information for Syros Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.